BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10030258)

  • 21. An approach to reduce treatment and invasive staging in childhood Hodgkin's disease: the sequence of the German DAL multicenter studies.
    Schellong G; Brämswig JH; Schwarze EW; Wannenmacher M
    Bull Cancer; 1988; 75(1):41-51. PubMed ID: 3282575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG.
    Rueffer U; Sieber M; Josting A; Breuer K; Grotenhermen FJ; Bredenfeld H; Tesch H; Nisters-Backes H; Engert A; Diehl V
    Ann Oncol; 1999 Nov; 10(11):1343-8. PubMed ID: 10631463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies.
    Kim HK; Silver B; Li S; Neuberg D; Mauch P
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):556-60. PubMed ID: 12738333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
    Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
    J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
    Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
    Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
    Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
    J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care. Australasian Radiation Oncology Lymphoma Group.
    Barton M; Boyages J; Crennan E; Davis S; Fisher RJ; Hook C; Johnson N; Joseph D; Liew KH; Morgan G
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):227-36. PubMed ID: 7836074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression.
    Vlachaki MT; Hagemeister FB; Fuller LM; Besa PC; Hess MA; Brown B; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):593-9. PubMed ID: 9231684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subdiaphragmatic Hodgkin's disease: the University of Florida experience.
    Hull MC; Mendenhall NP; Colgan ME
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):161-6. PubMed ID: 11777634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.
    Fermé C; Lepage E; Brice P; D'Agay MF; Fermand JP; Castaigne S; Frija J; Miot C; Marty M; Gisselbrecht C
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):397-405. PubMed ID: 7685749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
    Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
    Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
    Liao Z; Ha CS; Vlachaki MT; Hagemeister F; Cabanillas F; Hess M; Tucker S; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):971-7. PubMed ID: 11429225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
    Press OW; LeBlanc M; Lichter AS; Grogan TM; Unger JM; Wasserman TH; Gaynor ER; Peterson BA; Miller TP; Fisher RI
    J Clin Oncol; 2001 Nov; 19(22):4238-44. PubMed ID: 11709567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of stage and treatment modality on the likelihood of second malignancies and hematopoietic disorders in Hodgkin's disease.
    Mendenhall NP; Shuster JJ; Million RR
    Radiother Oncol; 1989 Mar; 14(3):219-29. PubMed ID: 2710953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control.
    Mendenhall NP; Rodrigue LL; Moore-Higgs GJ; Marcus RB; Million RR
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):551-61. PubMed ID: 10348284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.
    Vlachaki MT; Ha CS; Hagemeister FB; Fuller LM; Rodriguez MA; Besa PC; Hess MA; Brown B; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):609-16. PubMed ID: 9336140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for positive surgical staging in patients with Hodgkin's disease.
    Mauch P; Larson D; Osteen R; Silver B; Yeap B; Canellos G; Weinstein H; Rosenthal D; Pinkus G; Jochelson M
    J Clin Oncol; 1990 Feb; 8(2):257-65. PubMed ID: 2299369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.